Digital Transformation in Biopharma – A Review’

Over the last three decades, the cost of drug R&D has increased by ten-fold. As a result, biopharmaceutical companies are looking for new ways to approach modern day drug hunting. The ongoing COVID-19 pandemic has been a catalyst for many organisations to embrace the opportunities that digitisation brings.
D4 Pharma’s report ‘Digital Transformation in Biopharma – A Review’ provides unique insights and lessons learned from biopharma in this digital revolution. This report highlights how digital strategies can improve R&D, and how the companies that are adopting these strategies are increasing efficiencies within their organisations and dealing with emerging challenges.

 

What’s inside?
  • Chapter 1: Why be a digital pharma player? A discussion of the motivations behind digitisation at scale and why it is important to keep up.
     
  • Chapter 2: Increasing velocity in preclinical R&D. In this chapter, we focus on how preclinical R&D represents a huge opportunity to improve productivity challenges.
     
  • Chapter 3: Automation in drug discovery. This chapter covers ways in which modern automated technology can transform the R&D lab into the lab of the future – from wet lab pipetting techniques to LIMS.
     
  • Chapter 4: Harnessing AI/ML for R&D. AI and ML are transforming the industry. In this chapter, the role of AI and ML in drug discovery are explored as well as the challenges to its widespread adoption.
     
  • Chapter 5: Digitising clinical trials. Clinical trials are changing. This chapter will look at how digitisation is impacting clinical trials – from data collected via wearables to increasing patient engagement through communication channels.
     
  • Chapter 6: Harnessing data and analytics at scale. An exploration of the various ways pharma are looking to transform the way they analyse data.
     
  • Chapter 7: Grand challenges to adoption. Despite the promise of digitisation, several challenges remain. This chapter highlights the challenges to adoption and these are being addressed by pharma now.
     
  • Chapter 8: The path towards digital pharma R&D. A summary of the digital path ahead and what this means for pharma R&D.
Contributors:
  • Cindy Novak, LCS, Lab operations, Systems Manager, Bristol Myers Squibb
     
  • Sonia Houston Pichardo, Digital Trials lead Europe, Boehringer Ingelheim
     
  • Sreetama Basu, Data Scientist, Merck
     
  • Casandra Mangroo, Vice President of Science, BenchSci

Front Line Genomics* take your privacy very seriously. By requesting information on this form we will also use your information on the basis of our legitimate interests to keep in contact with you about future editions of this and other similar events/products which may be of interest to you.  We will only ever use the information we collect or receive about you in accordance with our Privacy Policy.

We are able to produce and distribute this report for free because of the kind support of our sponsor. To keep these reports free, we make the details you leave on the form (above) available to our sponsor BenchSci. You can unsubscribe at any time by emailing richard@frontlinegenomics.com.


     Download Report

ABOUT US       CONTACT       ADVERTISE       PRIVACY POLICY   


Front Line Genomics Limited is registered in England and Wales. Company Number 10421716, VAT: GB 297 742 548.
Registered Office: J202, The Biscuit Factory, Drummond Road, London SE16 4DG

Front Line Genomics Copyright © 2021, All rights reserved.